Alivus Life Sciences Recommends Final Dividend of ₹5/Share; Q4FY26 Profit ₹162.61 Crore
Alivus Life Sciences reported audited financial results for FY26. The company recommended a final dividend of ₹5 per share. For Q4FY26, total income was ₹711.89 crore and profit after tax was ₹162.61 crore. For the full year FY26, profit after tax was ₹564.48 crore.
The recommendation of a dividend and the reporting of financial results are material information for shareholders, impacting investment decisions.
The company announced positive financial results and recommended a final dividend, which are generally viewed favorably by investors.
Alivus Life Sciences Limited announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors has approved these results and recommended a final equity dividend of ₹5 per equity share (250%) for the financial year 2025-26. This dividend is subject to shareholder approval at the upcoming Annual General Meeting.
The company reported a Total Income of ₹711.89 crore for the quarter ended March 31, 2026, with Total Expenses amounting to ₹4,960.96 crore. Profit Before Tax for the quarter was ₹2,157.99 crore, and Profit for the Period after tax stood at ₹1,626.61 crore. For the full financial year ended March 31, 2026, Total Income was ₹26,122.43 crore and Profit for the Year after tax was ₹5,644.83 crore.
The audited financial results were reviewed by the Audit Committee and approved by the Board of Directors on May 14, 2026. The auditors, Walker Chandiok & Co LLP, have issued an unmodified opinion on the financial results. The company also noted an exceptional item related to the statutory impact of new labor codes, amounting to ₹256.57 crore, impacting the profit before tax for the year.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.